#BEGIN_DRUGCARD DB01116

# AHFS_Codes:
Not Available

# ATC_Codes:
C02BA01

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Arfonad

# CAS_Registry_Number:
7187-66-8

# ChEBI_ID:
9728

# Chemical_Formula:
C22H25N2OS

# Chemical_IUPAC_Name:
3,5-dibenzyl-4-oxo-8$l^{4}-thia-3,5-diazatricyclo[6.3.0.0^{2,6}]undecan-8-ylium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Adjuvants, Anesthesia
Antihypertensive Agents
Ganglionic Blockers
Nicotinic Antagonists
Vasodilator Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.473

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Trimethaphan

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1

# InChI_Key:
InChIKey=CHQOEHPMXSHGCL-UHFFFAOYSA-N

# Indication:
For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.

# KEGG_Compound_ID:
C07174

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1116

# Mechanism_Of_Action:
Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphan's hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
365.512

# Molecular_Weight_Mono:
365.168759122

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451784

# Pharmacology:
Trimethaphan is indicated for production of controlled hypotension during surgery to reduce bleeding into the surgical field and also for rapid reduction of blood pressure in the treatment of hypertensive emergencies, especially in patients with acute dissecting aneurysm, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.

# Predicted_LogP_Hydrophobicity:
4.4

# Predicted_LogS:
-4.8

# Predicted_Water_Solubility:
6.65e-03 g/l

# Primary_Accession_No:
DB01116

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
23576

# PubChem_Substance_ID:
46508994

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00044

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Thimethaphan
Trimetaphan
Trimetaphanum

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:55 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Trimethaphan

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
BCHE

# Phase_1_Metabolizing_Enzyme_1_ID:
3923

# Phase_1_Metabolizing_Enzyme_1_Name:
Cholinesterase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P06276

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein (Probable)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7963258	Kurenny DE, Selyanko AA, Derkach VA, Gmiro VE, Skok VI: Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
8232788	Loiacono R, Stephenson J, Stevenson J, Mitchelson F: Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex. Neuropharmacology. 1993 Sep;32(9):847-53.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CHRNA10

# Drug_Target_1_GenBank_ID_Gene:
AJ278118

# Drug_Target_1_GenBank_ID_Protein:
12053839

# Drug_Target_1_GeneCard_ID:
CHRNA10

# Drug_Target_1_Gene_Name:
CHRNA10

# Drug_Target_1_Gene_Sequence:
>1353 bp
ATGGGGCTCCGGAGCCACCACCTCAGCCTGGGCCTTCTGCTTCTGTTTCTACTCCCTGCA
GAGTGCCTGGGAGCTGAGGGCCGGCTGGCTCTCAAGCTGTTCCGTGACCTCTTTGCCAAC
TACACAAGTGCCCTGAGACCTGTGGCAGACACAGACCAGACTCTGAATGTGACCCTGGAG
GTGACACTGTCCCAGATCATCGATATGGATGAACGGAACCAGGTGCTGACCCTGTATCTG
TGGATACGGCAGGAGTGGACAGATGCCTACCTACGATGGGACCCCAATGCCTATGGTGGC
CTGGATGCCATCCGCATCCCCAGCAGTCTTGTGTGGCGGCCAGACATCGTACTCTATAAC
AAGGCCGACGCGCAGCCTCCAGGTTCCGCCAGCACCAACGTGGTCCTGCGCCACGATGGC
GCCGTGCGCTGGGACGCGCCGGCCATCACGCGCAGCTCGTGCCGCGTGGATGTAGCAGCC
TTCCCGTTCGACGCCCAGCACTGCGGCCTGACGTTCGGCTCCTGGACTCACGGCGGGCAC
CAACTGGATGTGCGGCCGCGCGGCGCTGCAGCCAGCCTGGCGGACTTCGTGGAGAACGTG
GAGTGGCGCGTGCTGGGCATGCCGGCGCGGCGGCGCGTGCTCACCTACGGCTGCTGCTCC
GAGCCCTACCCCGACGTCACCTTCACGCTGCTGCTGCGCCGCCGCGCCGCCGCCTACGTG
TGCAACCTGCTGCTGCCCTGCGTGCTCATCTCGCTGCTTGCGCCGCTCGCCTTCCACCTG
CCTGCCGACTCAGGCGAGAAGGTGTCGCTGGGCGTCACCGTGCTGCTGGCGCTCACCGTC
TTCCAGTTGCTGCTGGCCGAGAGCATGCCACCGGCCGAGAGCGTGCCGCTCATCGGGAAG
TATTACATGGCCACTATGACCATGGTCACATTCTCAACAGCACTCACCATCCTTATCATG
AACCTGCATTACTGTGGTCCCAGTGTCCGCCCAGTGCCAGCCTGGGCTAGGGCCCTCCTG
CTGGGACACCTGGCACGGGGCCTGTGCGTGCGGGAAAGAGGGGAGCCCTGTGGGCAGTCC
AGGCCACCTGAGTTATCTCCTAGCCCCCAGTCGCCTGAAGGAGGGGCTGGCCCCCCAGCG
GGCCCTTGCCACGAGCCACGATGTCTGTGCCGCCAGGAAGCCCTACTGCACCACGTAGCC
ACCATTGCCAATACCTTCCGCAGCCACCGAGCTGCCCAGCGCTGCCATGAGGACTGGAAG
CGCCTGGCCCGTGTGATGGACCGCTTCTTCCTGGCCATCTTCTTCTCCATGGCCCTGGTC
ATGAGCCTCCTGGTGCTGGTGCAGGCCCTGTGA

# Drug_Target_1_General_Function:
Involved in neurotransmitter receptor activity

# Drug_Target_1_General_References:
11350119	Lustig LR, Peng H, Hiel H, Yamamoto T, Fuchs PA: Molecular cloning and mapping of the human nicotinic acetylcholine receptor alpha10 (CHRNA10). Genomics. 2001 May 1;73(3):272-83.
11752216	Sgard F, Charpantier E, Bertrand S, Walker N, Caput D, Graham D, Bertrand D, Besnard F: A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit. Mol Pharmacol. 2002 Jan;61(1):150-9.

# Drug_Target_1_HGNC_ID:
HGNC:13800

# Drug_Target_1_HPRD_ID:
09395

# Drug_Target_1_ID:
458

# Drug_Target_1_Locus:
11p15.5

# Drug_Target_1_Molecular_Weight:
49705

# Drug_Target_1_Name:
Neuronal acetylcholine receptor subunit alpha-10

# Drug_Target_1_Number_of_Residues:
450

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Neuronal acetylcholine receptor protein subunit alpha-10 precursor
MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLE
VTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYN
KADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGH
QLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYV
CNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGK
YYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQS
RPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWK
RLARVMDRFFLAIFFSMALVMSLLVLVQAL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-24

# Drug_Target_1_Specific_Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma

# Drug_Target_1_SwissProt_ID:
Q9GZZ6

# Drug_Target_1_SwissProt_Name:
ACH10_HUMAN

# Drug_Target_1_Synonyms:
NACHR alpha 10
Neuronal acetylcholine receptor subunit alpha-10 precursor
Nicotinic acetylcholine receptor subunit alpha 10

# Drug_Target_1_Theoretical_pI:
7.97

# Drug_Target_1_Transmembrane_Regions:
238-258
268-288
302-322
429-449

#END_DRUGCARD DB01116
